Evidence map›Paper›PMID 42563162›Full record

ArticleInternational journal for equity in health2026

Artemisinin resistance and Nigeria's malaria burden: urgent policy imperatives from the WHO World Malaria Report 2025!

Shuaibu Saidu Musa, Reuben Victor M Laguitan, Kehinde Precious Fadele, Reymark P Malinda, Abraham Fessehaye Sium, Don Eliseo Lucero-Prisno

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for equity in health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuaibu Saidu MusaSchool of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.ORCID 0000-0003-0138-3261
Reuben Victor M LaguitanDepartment of Medical Laboratory Science, College of Nursing and Allied Health Sciences, University of the Cordilleras, Baguio City, Philippines.ORCID 0009-0009-6514-6178
Kehinde Precious FadeleDepartment of Research, Global Health Focus, Kigali, Rwanda. fadeleprecious@gmail.com.ORCID 0000-0002-0464-4167
Reymark P MalindaDevelopment Communication Department, College of Arts and Sciences, Bukidnon State University, Malaybalay City, Bukidnon, Philippines.ORCID 0000-0001-7200-6661
Abraham Fessehaye SiumAfrica Health Sciences University Department of Obstetrics and Gynecology, King Faisal Hospital Rwanda, Kigali, Rwanda.ORCID 0000-0001-5812-0804
Don Eliseo Lucero-PrisnoDepartment of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0002-2179-6365

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The WHO World Malaria Report 2025 highlights growing artemisinin resistance, with Nigeria bearing the world's highest malaria burden at risk. Although no validated resistance markers were found, non-canonical mutations correlate with delayed parasite clearance. The report urges Nigeria to implement multiple first-line therapies, expand surveillance, and diversify policy urgently.

Indexed as

AntimalarialsArtemisininsDrug ResistanceMalariaHealth PolicyHumansNigeriaPlasmodium falciparumWorld Health OrganizationAntimalarialsartemisininArtemisinins

Identifiers

PMID42563162
PMCPMC13445766

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.